Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

This trial (IGNITE MCL) is testing a combination of three drugs — glofitamab, ibrutinib, and obinutuzumab — to treat a type of blood cancer called Mantle Cell Lymphoma (MCL). The goal is to see if this combination works better than standard treatments, especially for younger patients with high-risk disease. **You may be eligible if...** - You are 18–64 years old with high-risk MCL features, such as certain gene mutations (p53, KMT2D, NOTCH1, etc.), a blastoid or aggressive cell appearance, or complex chromosomal abnormalities - OR you are 65 or older with MCL who cannot tolerate intensive stem cell transplant treatment - Your MCL has been confirmed by biopsy showing the characteristic chromosome change (t(11;14)) or cyclin D1 overexpression - You have not previously been treated with ibrutinib or other BTK inhibitors **You may NOT be eligible if...** - You have previously received ibrutinib, acalabrutinib, or similar drugs - You have uncontrolled heart rhythm problems (atrial fibrillation) or are on blood thinners that cannot be safely paused - You have active central nervous system (brain) lymphoma involvement - You have serious liver, kidney, or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.